#USA #Atlanta #Lundbeck #bexicaserin #DEEs

Lundbeck's Presentation at AES 2025: A Breakthrough in Childhood Epilepsy Treatment

Lundbeck is poised to revolutionize the treatment of rare childhood-onset epilepsies, particularly those classified under Developmental and Epileptic Encephalopathies (DEEs), as it showcases its investigational compound, Bexicaserin (LP352), at the 2025 American Epilepsy Society (AES) Annual Meeting. Scheduled to take place in Atlanta, USA, from December 5 to 9, this pivotal event will present compelling new findings acknowledging the potential of Bexicaserin in reducing seizure frequency in vulnerable pediatric patients.

Key Findings

The recent data unveiled at the annual meeting emphasizes the rapid and lasting impact of Bexicaserin on seizure control, with indications of decreased seizure occurrences as early as two weeks after initiating treatment. The comprehensive analysis includes outcomes from the early-phase PACIFIC trial, complemented by an Open-Label Extension (OLE) study, revealing that these reductions in seizure frequency can be maintained over a full year.

DEEs, characterized by both drug-resistant seizures and significant developmental delays, place considerable limitations on affected children, often leaving families without effective treatment options. In fact, most DEEs have shown resistance to conventional anti-seizure medications, leading to a pressing need for innovative therapies.

Lundbeck’s Commitment

With eight presentations scheduled at AES 2025, Lundbeck reinforces its dedication to addressing challenges faced by patients suffering from these debilitating disorders. Johan Luthman, EVP and Head of Research & Development at Lundbeck, stressed the importance of these findings, indicating that Bexicaserin's efficacy may position it as a leading therapeutic option across various DEE syndromes.